CardioFocus announced today that its board of directors promoted chief operating officer Burke Barrett as its new CEO, effective Jan. 19, 2020.
The 30-year veteran joined CardioFocus in 2002 and held roles ranging from vice president though president and COO, according to a news release. Before CardioFocus, Barrett served as VP of clinical operations at Cyberkinetics Neurotechnology Systems.
Barrett also served as Cyberonics VP of business & technology development and held roles in business development, clinical & regulatory affairs and quality auditing in the early stages of his career.
Marlborough, Mass–-based CardioFocus develops ablation treatment for cardiac disorders such as atrial fibrillation (Afib). The company’s HeartLight ablation system is intended to perform pulmonary vein isolation procedures using laser energy to block the abnormal electrical pathways that cause Afib.
The HeartLight X3 system uses direct tissue visualization, titratable laser energy and compliant balloon technology alongside a motor control system to allow for high-speed, circumferential lesion creation. In March CardioFocus won CE Mark approval for the HeartLight X3. In May, the company raised $55 million for the HeartLight catheters, taking its total amount of money raised to $159 million since 2009.
“The board of directors are proud to announce Burke’s promotion to CEO,” CardioFocus executive chairman Paul LaViolette said Burke has played an integral role developing the HeartLight platform.
“He is intimately familiar with our technology, employees, investors, customers, regulators, vendors and distributors, and is the perfect person to lead the company as we introduce the breakthrough HeartLight X3 system to the global Afib market,” LaViolette said of Burke in a news release.
Barrett added: “I am as excited as ever about the future of CardioFocus given the impressive clinical and commercial results coming out of Europe with our HeartLight X3 system. We are pleased to showcase the System at the 25th Annual International AF Symposium being held in Washington D.C. this week and plan to provide an update about the regulatory path and timeline for introduction of the system into the U.S. market in the coming weeks.”